Compare · CI vs ISR
CI vs ISR
Side-by-side comparison of The Cigna Group (CI) and IsoRay Inc. (ISR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and ISR operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.58B, about 1498.9x ISR ($51.1M).
- CI has hit the wire 4 times in the past 4 weeks while ISR has been quiet.
- CI has more recent analyst coverage (25 ratings vs 1 for ISR).
- Company
- The Cigna Group
- IsoRay Inc.
- Price
- $289.26-0.08%
- $0.38-1.03%
- Market cap
- $76.58B
- $51.1M
- 1M return
- +1.87%
- -
- 1Y return
- -7.06%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 1
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
IsoRay Inc.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest ISR
- IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)
- Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)
- Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)
- Williamson Robert F Iii bought $25,478 worth of shares (51,996 units at $0.49), increasing direct ownership by 220% to 75,676 units (SEC Form 4)
- SEC Form D filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 424B5 filed by IsoRay Inc.